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Riuretic Use, Progressive Heart Failure,
nd Death in Patients in SOLVD
read with great interest the study by Domanski et al. (1) on
iuretic use and outcome of heart failure. The first question that
omes to mind is whether patients taking non–potassium-sparing
iuretics (PSDs) were sicker than patients taking PSDs consider-
ng the weak diuretic action of PSDs. The fact that 25% of patients
n the PSDs-only group were receiving beta-blockers is indicative
f a relatively “healthy” group. Thus, it might have been appro-
riate to exclude these patients from study. In the multivariate
nalysis, the investigators should consider including two variables
ndicative of the severity of heart failure, namely elevated jugular
enous distention and a third heart sound. These two clinical signs
ave previously been found in the Studies Of Left Ventricular
ysfunction (SOLVD) to be independently associated with ad-
erse outcome (2).
Thus, the issue of confounding by the severity of heart failure
ould be more adequately addressed by providing data on jugular
enous distention and a third heart sound and including them in
he multivariate analysis.
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e appreciate Dr. Ghali’s interest in our report and respond to his
pecific points as follows:
First, Dr. Ghali suggests excluding patients in the potassium-
paring diuretics (PSD)-only group on beta-blockers because they
re more healthy. In fact, beta-blocker use was included in the
ultivariate analysis in our study. To exclude them from the
nalysis is not justified, and, in fact, would represent a serious
ethodological error.
Second, the state of the disease is captured in the New York
eart Association (NYHA) functional class and in the ejection
raction included in the multivariate analysis. The presence or
bsence of a third heart sound and/or jugular venous distension is
ubject to substantial potential for ascertainment error and, weelieve, would be less reliable than the indicators of disease severity
rovided.
Finally, although only a prospective randomized study will offer
definitive answer, we believe that emerging data, such as the
ALES study with the PSD spironolactone, support our findings.
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ympathetic Nervous System
ctivation in Chagasic
atients With Congestive Heart Failure
he pathogenesis and the medical treatment of chronic Chagas’
isease are still subjects of intense controversy and research (1–5).
n the study by Roveda et al. published in the Journal (6), exercise
raining decreased sympathetic nervous system activation in pa-
ients with congestive heart failure. It should be pointed out that 5
f 16 patients were of chagasic etiology (31.25%). As stated by the
nvestigators, four of these patients were in the sedentary group
nd one in the exercise group. The former continued to have
ncreased sympathetic activity, whereas the latter showed a signif-
cant and beneficial decrease in the degree of sympathetic activa-
ion. Moreover, resting muscle sympathetic nerve activity was now
imilar to trained healthy control subjects.
These findings raise several relevant questions: Was the degree
f sympathetic nervous system activation of chagasic patients
imilar to that of non-chagasic patients? If so, chagasic patients
ith congestive heart failure do not have sympathetic dysautono-
ia (7–9). Also, are the mechanisms responsible for sympathetic
ctivation and exercise training-induced beneficial effects in cha-
asic patients similar to those of non-chagasic patients (10,11)?
inally, do these results indirectly suggest that chagasic patients
ith congestive heart failure would benefit from therapeutic
trategies that antagonize sympathetic nervous system activation
12)?
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e agree with Dr. Davila that the pathogenesis and medical
reatment of chronic Chagas’ disease is complex and warrants
urther research. In our study, which included only a small number
f patients with Chagas’ disease, there was no significant difference
n sympathetic activation between Chagas and non-Chagas etiol-
gies of heart failure (Fig. 2A of reference 1). This finding is in
greement with some (2,3), but not all (4) prior investigations. Of
ote, uniquely in our study, efferent muscle sympathetic nerve
ctivity was measured directly utilizing microneurography, a sensi-
ive and reproducible technique, rather than indirectly with plasma
orepinephrine levels. Studies of the sympathetic activation in
hagas’ disease, which include patients with and without overt
ystolic dysfunction, may be able to distinguish between sympa-
hetic dysregulation attributable to T. cruzi infiltration of cardiac
erves/autonomic ganglia and that attributable to the cardiac
ysfunction present late in Chagas’ disease.
Although many hypotheses have been advanced to explain the
ympathetic activation in heart failure, including baroreceptor
ysfunction, overactivity of the arterial and/or muscle chemore-
eptors, or abnormalities in the “heart failure milicu,” the exact
echanisms have not been established. It remains unknown
hether the same mechanisms underlie the sympathetic activation
n Chagas’ heart disease. Finally, the findings in our study lend
upport to the concept that, regardless of the etiology of left
entricular dysfunction and heart failure, a chronic exercise regi-
en is sympatholytic and beneficial. Studies enrolling larger iumbers of patients with Chagas’ heart disease are underway in our
aboratory in the hope of answering this question definitively.
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ssessment of Diastolic Function
sing Myocardial Velocity Gradient
read with interest an editorial comment by Dr. Shah (1)
egarding a study on myocardial velocity gradient (MVG) and left
entricular dysfunction (2). I agree with his comment that no
oninvasive measure of “pure” diastolic function has yet been
chieved.
In his comment, Dr. Shah stated that diastolic MVG measure-
ent was first reported by Fleming et al. (3) as being somewhat
nsensitive to preload or atrial filling pressures. To my knowledge,
owever, in 1994, MVG was introduced merely for the evaluation
f myocardial contractility. Fleming et al. compared the velocity
radient with wall-thickness change to validate the new method-
logy (3). The application of MVG to assess diastolic dysfunction
ad to wait until the report by Palka et al. (4) differentiating
ypertrophic cardiomyopathy from athletes’ hearts, in which,
owever, they did not assess the effects of preload alterations.
elative independence of MVG from preload alterations as com-
ared to transmitral flow patterns was first reported by Shimizu et
l. (5) in 1998. In addition, I would like to emphasize that a robust
spect of the tissue Doppler technique is the potential to assess
egional, rather than global, diastolic function noninvasively,
hich should be validated and clinically applied in the near future.
Although the editorial comment by Dr. Shah raises an impor-
ant issue in the assessment of diastolic function and thus is very
nformative, I am afraid his statement on the application of MVG
easurements for the assessment of diastolic function seems to benaccurate.
